00:28 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Antabio raises EUR7.3M series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) on Oct. 16 in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors...
22:13 , Oct 16, 2017 |  BC Extra  |  Financial News

Antabio raises €7.3M in series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors of bacterial metalloenzymes...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

AntaBio, The Wellcome Trust deal

AntaBio received a €1.7 million ($2.3 million) milestone payment from The Wellcome Trust under a 2013 deal to develop a small molecule pan-inhibitor of bacterial metallo-beta-lactamases to treat multidrug-resistant Gram-negative bacterial infections. AntaBio triggered the...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Financial News

AntaBio completes venture financing

AntaBio , Labege, France   Business: Infectious   Date completed: 11/13/13   Type: Venture financing   Raised: €742,000 ($991,446)   Investor: Bpifrance  ...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

AntaBio, Galapagos deal

Galapagos' Argenta Discovery Ltd. service division will provide medicinal chemistry, computer-aided drug design and ADME/PK services for AntaBio to discover and develop candidates against bacterial targets. Galapagos said AntaBio will have exclusive rights to any...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

AntaBio, The Wellcome Trust infectious news

AntaBio received €4.7 million ($6.4 million) in Seeding Drug Discovery Initiative Funding from the Wellcome Trust to develop a small molecule pan-inhibitor of bacterial metallo-beta-lactamases to treat infections caused by multi-drug-resistant Gram-negative bacteria. The three-year...
07:00 , Oct 8, 2012 |  BioCentury  |  Finance

Rewarding the crowd

Rewarding the crowd While questions remain about how and when a crowd-funding mechanism will be put in place in the U.S., a French biotech last week said its crowd-sourced seed investors achieved a successful exit....